



December 15, 2021

Company name: SanBio Co., Ltd.  
Representative: Keita Mori, Representative Director  
and President  
(TSE Mothers Code: 4592)  
Contact: Yoshihiro Kakutani, Corporate Officer  
of Management Administration  
(TEL. +81-3-6264-3481)

### **Notice on Conclusion of Committed Credit Line Agreement with Resona Bank, Ltd.**

SanBio Company Limited (hereafter, “the Company”) hereby announces that today it entered into a committed credit line agreement with Resona Bank, Ltd.

For its SB623 development program in Japan targeting chronic effects of traumatic brain injury, the Company has been consulting with the Pharmaceuticals and Medical Devices Agency (PMDA) under the framework of Sakigake (expedited review) Designation System with the aim of applying for approval as soon as possible. The funds obtained based on the terms of the agreement are scheduled to be allocated to the establishment of post-launch manufacture, distribution, and marketing infrastructure for SB623, assuming approval is granted.

Funding method	Total committed amount (of which, used credit)	Agreement date	Expiration date (repayment date)	Remarks
Committed credit line	1.0 billion yen (none)	December 2021	June 2023 (June 2023)	The committed credit line will commence on January 14, 2022.  Main conditions of the agreement: During the terms of the agreement, the Company must maintain net assets and after-tax income above their corresponding amounts indicated in the business plan the Company submitted.

This development is expected to have only a marginal impact on the Company Group’s consolidated earnings performance for the fiscal year ending January 2022.

## References

### Summary of fund procurement

<Fiscal year ending January 2022>

Counterparty (lender)	Funding method	Amount of funds procured	Agreement (or approval) date	Use of funds
MUFG Bank, Ltd.	Committed credit line	2.0 billion yen	Aug. 2021	Establishment of post-launch manufacture, distribution, and marketing infrastructure for SB623
		Total 2.0 billion yen		

<Fiscal year ended January 2021>

Counterparty (lender)	Funding method	Amount of funds procured	Agreement (or approval) date	Use of funds
Mizuho Bank, Ltd.	Committed credit line with an option to extend the term of the loan	2.0 billion yen	Dec. 2020	- Establishment of post-launch manufacture, distribution, and marketing infrastructure for SB623
Mizuho Bank	Term loan with a commitment period	2.6 billion yen	Dec. 2020	- Establishment of post-launch manufacture, distribution, and marketing infrastructure for SB623
		Total 4.6 billion yen		

<Fiscal year ended January 2020>

Counterparty (lender)	Funding method	Amount of funds procured	Agreement (or approval) date	Use of funds
	Equity financing (accelerated book building [ABB])	7.1 billion yen		- Increase in the number of contract manufacturers to enhance mass production capabilities in anticipation of higher demand in Europe and the US - Manufacturing to build inventory of SB623 for chronic effects of traumatic brain injury in Japan

<Fiscal year ended January 2019>

Counterparty (lender)	Funding method	Amount of funds procured	Agreement (or approval) date	Use of funds
Mizuho Bank	Committed credit line	2.0 billion yen	Dec. 2018*1	- Establishment of post-launch manufacture, distribution, and marketing infrastructure for SB623
MUFG Bank	Committed credit line	2.0 billion yen	Nov. 2018*1	- Establishment of post-launch manufacture, distribution, and marketing infrastructure for SB623
Sumitomo Mitsui Banking Corp.	Committed credit line	1.0 billion yen	Nov. 2018*1	- Establishment of post-launch manufacture, distribution, and marketing infrastructure for SB623
	Equity financing (warrants with a provision to revise exercise price, via	11.0 billion yen		- Establishment of post-launch manufacture, distribution, and marketing infrastructure for SB623 - Development of SB623 for chronic

	third-party allotment)			effects of ischemic stroke in Japan, and R&D to expand development regions for the drug with an eye toward future sales - R&D to expand indications for SB623 and to in-license new substances
		Total 16.0 billion yen		

<Fiscal year ended January 2018>

Counterparty (lender)	Funding method	Amount of funds procured	Agreement (or approval) date	Use of funds
MUFG Bank*2	Loan	900 million yen	Mar. 2017	- Development of SB623 for chronic effects of ischemic stroke in the US, and for chronic effects of traumatic brain injury in Japan and the US
California Institute for Regenerative Medicine (CIRM)	Subsidy	19 million US dollars	Jun. 2017	- Development of SB623 for chronic effects of ischemic stroke in the US
Mizuho Bank	Committed credit line	1.6 billion yen	Aug. 2017*1	- Reserve for development of SB623 for chronic effects of traumatic brain injury in Japan and the US
MUFG Bank*2	Committed credit line	500 million yen	Oct. 2017*1	- Reserve for development of SB623 for chronic effects of traumatic brain injury in Japan and the US
		Total 5.09 billion yen		

<Fiscal year ended January 2017>

Counterparty (lender)	Funding method	Amount of funds procured	Agreement (or approval) date	Use of funds
Mizuho Bank	Committed credit line	1.0 billion yen	Mar. 2016*1	Reserve for development of SB623 for chronic effects of traumatic brain injury in Japan and the US

Note 1: As of December 15, these agreements had expired as their terms had come to an end.

Note 2: Due to restructuring by function of Mitsubishi UFJ Financial Group, Inc., the counterparty (lender) was changed from Mitsubishi UFJ Trust and Banking Corp. to MUFG Bank, Ltd.